Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
Pfizer licenses CAR-T therapies from China's Starna in up to $2.6B deal
00

Pfizer licenses CAR-T therapies from China's Starna in up to $2.6B deal

Nov 18, 2026

Pfizer signed an exclusive licensing deal with China's Starna Therapeutics on November 18, 2026, worth up to $2.6 billion, including $330 million upfront and up to $2.3 billion in milestones. The agreement covers three pre-clinical in vivo CAR-T therapies for autoimmune diseases outside Greater China. The deal follows Pfizer's $10.5 billion agreement with Innovent Biologics in May 2026 and an earlier 2025 deal with 3SBio.

Pfizer-Starna licensing deal

  • ▪The three CAR-T therapies Pfizer licensed from Starna Therapeutics for autoimmune diseases have not yet entered human trials as of November 18, 2026
  • ▪Starna Therapeutics will receive royalties on sales of any approved products under the Pfizer licensing agreement
  • ▪Pfizer struck an exclusive licensing agreement with China's Starna Therapeutics to develop three CAR-T therapies for autoimmune diseases
  • ▪Pfizer will pay Starna Therapeutics $330 million upfront under the licensing agreement
  • ▪Pfizer could pay Starna Therapeutics up to $2.3 billion more if the treatments meet development, regulatory, and sales milestones
  • ▪The Pfizer-Starna licensing deal is worth up to $2.6 billion in total
  • ▪The Pfizer-Starna agreement gives Pfizer rights to develop and commercialize three early-stage autoimmune disease programs outside Greater China

CAR-T therapy technology

  • ▪In vivo CAR-T therapies are designed to genetically reprogram immune cells directly inside the body to target and eliminate disease-causing immune cells
  • ▪Conventional CAR-T treatments involve collecting and re-engineering a patient's cells outside the body before reinfusing them

Pfizer growth strategy

  • ▪Pfizer's licensing deal with Starna Therapeutics is part of the company's strategy of partnering with Chinese biotechs to drive growth
  • ▪Pfizer is seeking to reignite growth by 2028 while preparing for a wave of patent expirations and continued declines in COVID-related revenue

2 sources

Reuters
Pfizer licenses CAR-T therapies from China's Starna in up to $2.6 billion deal | Reuters
View source article
Endpoints
Pfizer gets into in vivo CAR-T through licensing deal with Chinese biotech
View source article

Story comments

Loading comments…

Related entities

PfizerUnited StatesChina

Topics

CAR T-cell therapyAutoimmune disease treatmentsCorporate strategyPharmaceutical IndustryDrug developmentImmunotherapyBiotechnology